GH SecretagoguesCompoundableS

CJC-1295

CJC-1295 DAC

CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
4
Research grade
S
Community score
175

Trend index

Trackers
3,142

Overview

About CJC-1295

CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.

Category
GH Secretagogues
Regulatory status
Compoundable
Also known as
CJC-1295 DAC
Self-reports
33

Community

What 33 users report

33 community reports

Positive 96% · Neutral 4% · Negative 0%

Most reported benefits

Energy
138
Sleep
138

Most reported side effects

Fatigue
2
Headache
2
Water retention
1

Dose distribution

Median: 400–600 mcg · Most common: 200–400 mcg

0–25
0
25–50
0
50–100
0
100–200
24
200–400
39
400–600
23
600–1000
0
1000–2000
31
2000+
21

How repeat users are trending

Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 48 days · Based on 25 repeat reporters

Research

Cited research (2)

PubMed

Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295

Teichman et al., 2006

Source
Wiki study page →

Help

Frequently asked

What do PeptIQ users report about CJC-1295?

This page summarizes 33 anonymized self-reports from PeptIQ users who track CJC-1295, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for CJC-1295?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is CJC-1295 safe to use?

This wiki does not assess safety or recommend use. CJC-1295 is listed as Compoundable. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of CJC-1295?

Research, primarily in animal models, suggests CJC-1295 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of CJC-1295?

CJC-1295 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified CJC-1295 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of CJC-1295?

The safety and effectiveness of CJC-1295 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on CJC-1295?

While there are over 200 published studies on CJC-1295, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source